aTyr Pharma, Inc.(US:ATYR) Prnewswireยท2025-10-27 23:38Core Viewpoint - aTyr Pharma, Inc. is facing a class action lawsuit due to allegations of misleading investors regarding the efficacy of its drug candidate, Efzofitimod, during a clinical trial for pulmonary sarcoidosis [1][2]. Group 1: Allegations and Study Results - The lawsuit claims that aTyr's executives provided misleading information about the Phase 3 study's design and the drug's ability to allow patients to taper steroid usage completely [2]. - On September 15, 2025, aTyr announced that the EFZO-FIT study did not meet its primary endpoint, specifically the change from baseline in mean daily OSC dose at week 48 [3]. - Following the announcement, aTyr's stock price plummeted from $6.03 per share on September 12, 2025, to $1.02 per share on September 15, 2025, marking an 83.2% decline in a single day [3]. Group 2: Class Action Participation - Shareholders interested in participating in the class action must submit their papers to the court by December 8, 2025, to serve as lead plaintiff [4]. - Shareholders do not need to participate in the case to be eligible for recovery and can remain absent class members if they choose [4]. Group 3: Legal Representation - Robbins LLP operates on a contingency fee basis, meaning shareholders pay no fees or expenses unless the case is won [5]. - The firm has a history of advocating for shareholder rights and aims to help recover losses and improve corporate governance [5].